1 October 2024 in Russian Ophthalmological Journal
Glaucoma is worldwide the most common cause of irreversible blindness. Its prevalence in the population older than 40 years is about 3.5 %, and correlates with age. The most common type is primary open-angle glaucoma (POAG). The global prevalence of POAG is expected to grow from 76.0 million in 2020 to 111.8 million by 2040. In 2022, a total of 1,250,558 patients with glaucoma were registered in the Russian Federation, of which 110,680 had newly diagnosed glaucoma. The overall glaucoma incidence rate in Russia shows a steady growth: in 2022, it increased by 30 % as compared to 2013. In order to meet the challenge, medical care of glaucomatous patients is on the rise: the contingent receiving dispensary observation increased by 6.8 % over the last 10 years, whilst surgical treatment involved 28.1 % more patients.
2 July 2024 in Russian Ophthalmological Journal
Glaucoma is one of the world’s primary causes of blindness. Russia is following the global increasing trends of glaucoma and its leading position among ophthalmic pathologies that cause irreversible loss of vision. Elevated intraocular pressure (IOP) is the only modifiable risk factor of glaucoma, so treatment strategies specifically focus on reducing IOP by suppressing the production of intraocular fluid and boosting its outflow. The current review presents new medications aimed at glaucoma and high IOP control that have recently appeared at the international market as well as the drugs under the different stages of development, from experimental to clinical studies. These include both the developments of agents belonging to the existing classes and of entirely new drugs intended to control IOP. In an attempt to reduce the side effects of locally administered drugs and prolong their action, in parallel with the development of new drugs, there is also evidence of alternative methods of drug delivery: intraocular implants, injectable forms and obturators, combinations of polymers and colloidal systems.
2 January 2023 in Ophthalmology in Russia
Alpha2-macroglobulin (α2-MG) is a multifunctional glycoprotein. Due to the variety of its functions there can be several ways of its involvement in the pathogenesis of the glaucomatous optic neuropathy, including neuroinflammation, amyloid deposition, neurotoxicity. It is known that α2-MG level in aqueous humor is increased in glaucoma but there is scant information about its concentration in blood and tear fluid.Purpose. To determine the α2-MG activity in tear fluid and blood serum of glaucoma patients to broaden of understanding of its role in the pathogenesis of glaucoma and to estimate its informativity for the characterization of the disease clinical course.Methods. Tear fluid was collected from 21 patients with primary open-angle glaucoma and 17 healthy adults. Activity of α2-MG was measured enzymatically with BAPNA as a substrate.Results. Activity of α2-MG in tears was 20 times lower than in blood serum. In healthy controls it was 4.66 ± 0.27 nmol / min×ml in tears and 92.35 ± 5.44 nmol / min×ml in blood. Totally in glaucoma patients it was 54 % higher than in controls in tears (р < 0.008), and 35 % higher in blood (р < 0.05). Particularly patients without pseudoexfoliative syndrome showed a significant α2-MG activity increase in tears (2 times) while in serum it was 67 % higher than in controls. In patients with pseudoexfoliative glaucoma α2-MG activity was not increased in tears nor in blood.Conclusion. Primary open-angle glaucoma without pseudoexfoliative syndrome cause the increase of α2-MG activity in tears and in blood in contrast with pseudoexfoliative glaucoma. This fact indicates that pathogenetic ways of these types of glaucoma are different. The increased α2-MG activity may be the risk factor for the development of glaucoma without pseudoexfoliative syndrome.
14 June 2025 in Russian Ophthalmological Journal
Study of factors preventing excessive scarring in antiglaucoma surgery creates a foundation for developing methods of influencing these processes in the postoperative period in order to increase the effectiveness of the intervention. Analysis of the literature showed that a systematic approach to preparing for successful surgical treatment of glaucoma should include a rational choice of previous hypotensive therapy with preservative-free drugs, prevention of damage to the ocular surface using tear substitute and immunosuppressive therapy, as well as preoperative anti-inflammatory prophylaxis with steroid and non-steroid agents with proven ophthalmic hypertension safety.
9 January 2026 in Russian Ophthalmological Journal
Purpose: to evaluate the efficacy and safety of Preserflo MicroShunt implantation in patients with primary open-angle glaucoma (POAG) as the first and second glaucoma surgery in the early postoperative period. Material and methods. Single-center prospective non-randomized study of Preserflo MicroShunt implantation in 12 patients (12 eyes) aged 60,4 ± 17,8 with moderate and advanced POAG with an average IOP of 30.3 ± 9.1 mm Hg. IOP was determined at 1, 3, 7 days, 2 weeks, 1 and 3 months after surgery. Results. The IOP level was 10.2 ± 5.0, 9.4 ± 4.4, 11.3 ± 4.5, 10.8 ± 4.2, 12.7 ± 5.6 and 13.0 ± 6.1 mm Hg, respectively. Baseline average visual acuity was 0.5 ± 0.3, unchanged either on day 7 or by 3 month. Hypotony £ 6 mmHg was in 4 cases, with a flat anterior chamber and choroidal effusion without Seidel positive leakage in 2 cases, without anterior chamber reformation. In 5 cases, IOP increase required bleb needling filtration, and in 2 cases — the medication therapy restart. Conclusion. Preserflo MicroShunt implantation in patients with POAG is an effective and safe procedure for up to 3 months after surgery.
3 January 2022 in Russian Ophthalmological Journal
Purpose. To evaluate the efficacy and safety of Travapress Duo with respect to hypotensive results, changes in functional parameters, and adverse reactions. Material and methods. 30 patients aged 65–75 (averagely 71.3 ± 3.2 years) with a newly diagnosed primary open-angle glaucoma (POAG) received Travapress Duo in the evening, once a day. Goldman tonometry was performed during the screening, then 1 week, 1 month and 3 months from the treatment start. Static perimetry and optical coherence tomography (OCT) were performed before treatment and at the end of the 3rd month since the treatment start. Adverse events were recorded at each stage of the study.Results. As a result of a 3 month long therapy with Travapress Duo, a significant decrease in IOP was noted starting from the 1st week of instillations (by 34 %), after 1 month, by 35 % and after 3 months of observation by 36 %. By the end of the 3rd month of treatment, we noted an insignificant increase in visual acuity, a positive dynamic of the standard deviation and the standard deviation pattern, as well as OCT indicators, such as average thickness of the layer of retinal nerve fibers and the layer of retinal ganglion cells in the macula, stabilization of the thickness of the retinal ganglion cell complex layer and the size of the inner plexiform layer. One patient complained of discomfort and hyperemia by the end of the 1st week of drug instillation. No systemic side effects were noted during the follow-up, and in no case drug withdrawal was require. Conclusion. The preservative-free Travapress Duo drug displayed a high hypotensive efficacy, reducing the IOP to 36% of the initial value. The hypotensive effect was accompanied by indirect neuroprotection, which manifested itself in the positive changes observable in the results of functional studies with varying degrees of reliability. Travapress Duo is characterized by a low level of local side effects and can be recommended for both for the initial and long-term therapy of primary glaucoma of developed and advanced stages.